CO2019011299A2 - Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4 - Google Patents

Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4

Info

Publication number
CO2019011299A2
CO2019011299A2 CONC2019/0011299A CO2019011299A CO2019011299A2 CO 2019011299 A2 CO2019011299 A2 CO 2019011299A2 CO 2019011299 A CO2019011299 A CO 2019011299A CO 2019011299 A2 CO2019011299 A2 CO 2019011299A2
Authority
CO
Colombia
Prior art keywords
dialkoxystyryl
benzylsulfones
bioavailability
formulations
administration
Prior art date
Application number
CONC2019/0011299A
Other languages
English (en)
Inventor
Manoj Maniar
Original Assignee
Onconova Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59856606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019011299(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onconova Therapeutics Inc filed Critical Onconova Therapeutics Inc
Publication of CO2019011299A2 publication Critical patent/CO2019011299A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen composiciones farmacéuticas de (E)-2,4,6-trimetoxiestiril-3-[(carboximetil)amino]-4-metoxibencilsulfona y sales farmacéuticamente aceptables de la misma, así como métodos de su uso.
CONC2019/0011299A 2017-04-13 2019-11-12 Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4 CO2019011299A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485355P 2017-04-13 2017-04-13
PCT/US2018/027514 WO2018191634A2 (en) 2017-04-13 2018-04-13 Formulations with enhanced stability and bioavailability for administration of (e)-2,6- dialkoxystyryl 4-substituted benzylsulfones

Publications (1)

Publication Number Publication Date
CO2019011299A2 true CO2019011299A2 (es) 2020-02-18

Family

ID=59856606

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0011299A CO2019011299A2 (es) 2017-04-13 2019-11-12 Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4

Country Status (19)

Country Link
US (1) US10098862B1 (es)
EP (3) EP4193988B1 (es)
JP (1) JP7202313B2 (es)
KR (1) KR102643626B1 (es)
CN (2) CN110536678A (es)
AR (1) AR109503A1 (es)
AU (1) AU2018253291B2 (es)
BR (1) BR112019021445A2 (es)
CA (1) CA3058664A1 (es)
CL (1) CL2019002899A1 (es)
CO (1) CO2019011299A2 (es)
EA (1) EA201992436A1 (es)
ES (2) ES2926042T3 (es)
IL (2) IL269757B (es)
MX (1) MX2022011860A (es)
TW (2) TWI759459B (es)
UY (1) UY37380A (es)
WO (2) WO2018190897A1 (es)
ZA (2) ZA201906671B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11382877B2 (en) 2017-04-13 2022-07-12 Onconova Therapeutics, Inc. Formulation of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163607A0 (en) 2002-02-28 2005-12-18 Univ Temple Amino-substituted 2,6-dialkoxystyryl 4-substitutedbenzylsulfones for treating proliferative disorders
EP1773353B1 (en) 2004-07-19 2011-02-09 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones
CA2661983C (en) 2006-08-30 2015-05-05 Mount Sinai School Of Medicine Of New York University Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
JP2010515772A (ja) * 2007-01-16 2010-05-13 オンコノバ・セラピューティックス・インコーポレーテッド （ｅ）−２，６−ジアルコキシスチリル４−置換ベンジルスルホン類の非経口投与用製剤
CN109157535A (zh) * 2012-02-14 2019-01-08 赛多斯有限责任公司 苯达莫司汀的制剂
JP6462582B2 (ja) * 2012-12-07 2019-01-30 オンコノバ・セラピューティックス・インコーポレーテッド がんの治療のための方法および組成物

Also Published As

Publication number Publication date
KR20190134705A (ko) 2019-12-04
MX2022011860A (es) 2022-10-20
EA201992436A1 (ru) 2020-03-30
AU2018253291B2 (en) 2024-05-02
ZA201906671B (en) 2022-03-30
ES2926042T3 (es) 2022-10-21
CL2019002899A1 (es) 2020-02-28
JP7202313B2 (ja) 2023-01-11
EP3733163B1 (en) 2022-06-08
IL269757A (en) 2019-11-28
ZA202107580B (en) 2023-11-29
ES2941538T3 (es) 2023-05-23
CA3058664A1 (en) 2018-10-18
TW202222303A (zh) 2022-06-16
WO2018191634A4 (en) 2019-06-20
EP3733163A1 (en) 2020-11-04
TWI759459B (zh) 2022-04-01
AR109503A1 (es) 2018-12-19
WO2018191634A2 (en) 2018-10-18
EP3609471A2 (en) 2020-02-19
KR102643626B1 (ko) 2024-03-06
IL269757B (en) 2022-08-01
TW201836597A (zh) 2018-10-16
EP3733163B8 (en) 2022-09-28
EP3609471B1 (en) 2023-01-04
JP2020516665A (ja) 2020-06-11
IL289806A (en) 2022-03-01
AU2018253291A1 (en) 2019-10-24
CN116637095A (zh) 2023-08-25
EP4193988A1 (en) 2023-06-14
UY37380A (es) 2018-10-31
EP4193988B1 (en) 2024-06-05
CN110536678A (zh) 2019-12-03
US20180296513A1 (en) 2018-10-18
TWI809721B (zh) 2023-07-21
IL289806B2 (en) 2024-06-01
WO2018191634A3 (en) 2019-04-11
WO2018190897A1 (en) 2018-10-18
IL289806B1 (en) 2024-02-01
US10098862B1 (en) 2018-10-16
BR112019021445A2 (pt) 2020-05-05

Similar Documents

Publication Publication Date Title
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
BR112015018087A8 (pt) composto, composição farmacêutica e uso
CO2017004714A2 (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
DOP2015000051A (es) Formulaciones acuosas estables de adalimumab
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CY1124059T1 (el) Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa
MX369818B (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY34542A (es) ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
PE20151427A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CO2019000643A2 (es) Formulaciones gastrorretentivas orales y usos de las mismas
CR10492A (es) Nuevos compuestos heterociclicos
DOP2019000184A (es) Inhibidores selectivos de jak1
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
CO2020007044A2 (es) Derivados de pirrol como inhibidores de acc
ECSP21030482A (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
CU20210077A7 (es) Extractos bacterianos estables como fármacos
CL2018000363A1 (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana.
CL2017001840A1 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas.
ES2850277R1 (es) Composiciones de administración farmacéutica y usos de las mismas
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
NI202000028A (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
CO2019011299A2 (es) Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4